Important studies recently reported that insulin exerts a neuroprotective effect and that decreased brain insulin levels and/or insulin and its receptors (IR)‐mediated signaling are linked to several age‐related neurodegenerative diseases. These findings were further potentiated by the recent hypothesis that insulin may constitute the potential missing link between diabetes and Alzheimer disease (AD) in the central nervous system (CNS), resulting in AD being called “type 3 diabetes.” In this regard, insulin could be a very promising therapy against diabetes‐ and age‐related neurodegenerative diseases. However, some studies (including longevity ones) have given controversial results on the beneficial effects of CNS insulin/IR activity. Herewith, the authors aim to critically analyze the pros and cons of insulin in the CNS, especially regarding age‐ and diabetes‐related neurodegeneration.
|Title of host publication||Metabolic Syndrome and Neurological Disorders|
|Editors||Tahira Farooqui, Akhlaq A. Farooqui|
|Publisher||John Wiley & Sons Ltd.|
|Number of pages||29|
|Publication status||Published - 15 Nov 2013|
- Alzheimer disease (AD)
- central nervous system (CNS)